Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CFO Scott Burrows sold 15,000 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $87.13, for a total transaction of $1,306,950.00. Following the transaction, the chief financial officer directly owned 97,994 shares of the company’s stock, valued at $8,538,217.22. The trade was a 13.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Spyre Therapeutics Price Performance
NASDAQ SYRE opened at $87.89 on Monday. The company has a market capitalization of $7.63 billion, a price-to-earnings ratio of -42.25 and a beta of 3.05. Spyre Therapeutics, Inc. has a twelve month low of $14.00 and a twelve month high of $102.06. The stock has a fifty day simple moving average of $76.42 and a 200 day simple moving average of $52.01.
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.08). Research analysts expect that Spyre Therapeutics, Inc. will post -2.86 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Read Our Latest Stock Analysis on SYRE
Institutional Trading of Spyre Therapeutics
Several hedge funds have recently modified their holdings of SYRE. Perceptive Advisors LLC grew its holdings in Spyre Therapeutics by 149.6% in the fourth quarter. Perceptive Advisors LLC now owns 3,069,225 shares of the company’s stock worth $100,548,000 after purchasing an additional 1,839,780 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Spyre Therapeutics by 13,969.3% during the fourth quarter. Janus Henderson Group PLC now owns 1,829,009 shares of the company’s stock valued at $59,918,000 after purchasing an additional 1,816,009 shares during the period. RA Capital Management L.P. acquired a new position in shares of Spyre Therapeutics during the fourth quarter valued at about $53,124,000. Remedium Capital Partners LLC bought a new position in shares of Spyre Therapeutics during the 4th quarter worth about $47,706,000. Finally, TCG Crossover Management LLC bought a new position in shares of Spyre Therapeutics during the 3rd quarter worth about $18,446,000. Institutional investors own 80.39% of the company’s stock.
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Featured Stories
- Five stocks we like better than Spyre Therapeutics
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
